Promising Ebola Vaccine Likely To Move On To Second Phase Trial
GENEVA, Dec 19 (Reuters) – Trials of GlaxoSmithKline’s experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information.
The World Health Organization, which hosted a meeting of national regulatory authorities and ethics committees earlier this week, said they had thoroughly discussed all aspects of the proposed trials at the two-day meeting.
“Reviewing countries requested additional documentation from the manufacturer of the vaccine, GlaxoSmithKline, before authorization of the trials,” the WHO said in a statement.
Countries where the trials are planned — Cameroon, Ghana, Mali, Nigeria and Senegal — should receive and review the additional information by the end of January.
“If these steps are completed to the satisfaction of the —> Read More Here